MedTrace Logo

Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany

NCT01155193 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30804

Last updated 2018-10-29

Study results available
· View outcomes & findings →

Summary

The SYNAGIS Registry was carried out in order to gather comprehensive real-world data on the use of palivizumab in children at high risk for serious respiratory syncytial virus (RSV) disease. This registry was designed as a post-marketing observational study, and conducted with the aim of collecting data on palivizumab administration, the risk factors for complicated RSV disease, frequency of hospitalizations, and drug adherence.

Conditions

  • Respiratory Syncytial Virus Infections

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Sandra Bloch, MD · AbbVie Deutschland GmbH & Co. KG, Medical Department

Eligibility

Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-01
Primary Completion
2016-07-31
Completion
2016-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01155193 on ClinicalTrials.gov